3908:HKEXChina International Capital Corp. Ltd. Class H Analysis
Data as of 2026-06-04 - not real-time
HK$19.12
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
China International Capital Corporation (3908.HK) trades at HK$19.12, well below its DCF fair value of HK$492.6, implying a ~46% upside. The stock sits just above the computed support of HK$18.91 and below resistance at HK$21.92, with the 20‑day SMA (HK$20.44) still higher than the current price, indicating short‑term pressure. Technical signals are mixed: the MACD is bearish (line –0.20 vs signal –0.01) and the RSI sits at 36, hinting at possible oversold conditions. Volatility over the past 30 days is elevated at ~31 % while beta is modest (~0.73), suggesting the share moves less than the market but can swing sharply. Fundamentals are strong: revenue has surged 63 % YoY, operating margin exceeds 51 %, and the PE of 8.8 is far below the industry average of 17. Dividend yield of 1.0 % is supported by a low payout ratio of 9.6 %.
Despite a high debt‑to‑equity ratio of 282 %, the balance sheet is cushioned by HK$532 bn of cash, giving ample liquidity. The company’s low price‑to‑book (0.78) and strong cash flow generation (HK$88 bn operating cash) reinforce the undervalued narrative. Analyst consensus is a “strong buy” with a median target of HK$28.3, reinforcing the upside potential. The combination of robust growth, attractive valuation, and sustainable dividend makes the stock a compelling buy across horizons. However, decreasing volume and regulatory headwinds in China add a modest risk element. Investors should consider a position now while monitoring support levels and policy developments.
Despite a high debt‑to‑equity ratio of 282 %, the balance sheet is cushioned by HK$532 bn of cash, giving ample liquidity. The company’s low price‑to‑book (0.78) and strong cash flow generation (HK$88 bn operating cash) reinforce the undervalued narrative. Analyst consensus is a “strong buy” with a median target of HK$28.3, reinforcing the upside potential. The combination of robust growth, attractive valuation, and sustainable dividend makes the stock a compelling buy across horizons. However, decreasing volume and regulatory headwinds in China add a modest risk element. Investors should consider a position now while monitoring support levels and policy developments.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 7/10
Key Factors
- MACD bearish but RSI near oversold
- Price near support level
- Decreasing volume suggests caution
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- 63% revenue growth YoY
- PE 8.8 vs industry 17 indicating value
- Sustainable dividend with low payout
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- Strong cash position relative to debt
- Strategic position in Chinese capital markets
- Long‑term DCF upside and analyst buy consensus
Key Metrics & Analysis
Financial Health
Revenue Growth63.50%
Profit Margin35.43%
P/E Ratio8.8
ROE8.89%
ROA1.47%
Debt/Equity281.62
P/B Ratio0.8
Op. Cash FlowHK$88.2B
Industry P/E17.0
Technical Analysis
TrendNeutral
RSI36.3
SupportHK$18.91
ResistanceHK$21.92
MA 20HK$20.44
MA 50HK$19.66
MA 200HK$20.38
MACDBearish
VolumeDecreasing
Fear & Greed Index93.93
Valuation
Fair ValueHK$492.60
Target PriceHK$27.99
Upside/Downside46.38%
GradeUndervalued
TypeBlend
Dividend Yield1.03%
Risk Assessment
Beta0.73
Volatility30.73%
Sector RiskMedium
Reg. RiskHigh
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.